Huntington National Bank Boosts Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Huntington National Bank increased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 4.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 277,377 shares of the medical equipment provider's stock after acquiring an additional 10,806 shares during the period. Intuitive Surgical comprises 1.0% of Huntington National Bank's holdings, making the stock its 21st largest holding. Huntington National Bank owned approximately 0.08% of Intuitive Surgical worth $136,267,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Creekmur Asset Management LLC raised its stake in Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 42 shares in the last quarter. Ridgewood Investments LLC bought a new position in shares of Intuitive Surgical in the 2nd quarter worth about $26,000. Delos Wealth Advisors LLC increased its holdings in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Godsey & Gibb Inc. boosted its stake in Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider's stock worth $29,000 after acquiring an additional 35 shares in the last quarter. Finally, LRI Investments LLC acquired a new stake in shares of Intuitive Surgical in the 1st quarter valued at about $30,000. 83.64% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Gary S. Guthart sold 18,151 shares of the firm's stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total value of $9,286,596.13. Following the completion of the sale, the chief executive officer now directly owns 24,219 shares in the company, valued at $12,391,166.97. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the firm's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the transaction, the senior vice president now owns 3,001 shares of the company's stock, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Gary S. Guthart sold 18,151 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares of the company's stock, valued at approximately $12,391,166.97. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,178 shares of company stock worth $45,897,071 over the last 90 days. Corporate insiders own 0.90% of the company's stock.

Intuitive Surgical Trading Up 0.8 %

Shares of ISRG traded up $4.34 during trading hours on Thursday, reaching $541.03. 582,191 shares of the stock traded hands, compared to its average volume of 1,455,345. Intuitive Surgical, Inc. has a 52-week low of $291.39 and a 52-week high of $544.38. The company has a market cap of $192.70 billion, a P/E ratio of 86.28, a price-to-earnings-growth ratio of 5.28 and a beta of 1.39. The company's 50-day moving average price is $496.95 and its two-hundred day moving average price is $455.65.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to analysts' expectations of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. On average, research analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Analyst Ratings Changes

ISRG has been the topic of a number of recent research reports. Robert W. Baird increased their target price on Intuitive Surgical from $503.00 to $565.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Redburn Atlantic raised shares of Intuitive Surgical from a "neutral" rating to a "buy" rating and raised their price target for the company from $380.00 to $510.00 in a research report on Friday, August 2nd. Stifel Nicolaus upped their price objective on shares of Intuitive Surgical from $475.00 to $525.00 and gave the stock a "buy" rating in a research report on Friday, October 18th. Mizuho upped their price objective on Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. Finally, BTIG Research set a $535.00 target price on Intuitive Surgical in a research report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $513.74.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.